What this study is
The purpose of this study is to assess the effectiveness of the Probation/Parole and Reentry Coach Application (PARCA)-a mobile application that allows justice-involved people to set and manage personal goals to support sustained, successful community supervision. Through this study, we aim to conduct surveys and interviews aimed to gain a better understanding of ways to improve the substance use treatment process, connections between clients and officers, and goal selection and achievement for clients using the PARCA app
What's being tested
- PARCA
Intervention · BEHAVIORAL
PARCA is an s an app to facilitate goal management, resource allocation, and managing progress.
Study details
- Sponsor
- George Mason University
- Conditions
- Behavioral Addiction
- Enrolling
- 50 people
- Starts
- 2025-03-01
- Est. completion
- 2027-05
- Design
- Open-label, randomized, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- All officers that supervise individuals All individuals on supervision that indicate drug use -
You can't join if
- Individuals that have poor performance on their job clients have serious mental health disorders
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (2)
2 openTravis County Community Services
Austin, Texas, United States
- Rudy Perez, MA · Contact5125086452Rudy.Perez@traviscountytx.gov
- Contactftaxman@gmail.com
- Faye Taxman, PhD · Principal investigator
RecruitingDallas County Community Supervision
Dallas, Texas, United States
- Arnold Patrick, MA · Contact9565876170arnold.patrick@dallascounty.gov
- Marta Kahn, Ph.D. · Contact9563766350marta.kahn@dallascounty.gov
- Faye S Taxman, PHD · Principal investigator
Recruiting
Study team
Sponsor
George Mason University
Study ID GeorgeMasonU
Principal investigator
Faye S. Taxman, PhD
George Mason University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.